Form 8-K - Current report:
SEC Accession No. 0001493152-24-021837
Filing Date
2024-05-29
Accepted
2024-05-29 17:29:22
Documents
14
Period of Report
2024-05-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39036
  Complete submission text file 0001493152-24-021837.txt   254003

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE lixt-20240524.xsd EX-101.SCH 3785
3 XBRL DEFINITION FILE lixt-20240524_def.xml EX-101.DEF 26651
4 XBRL LABEL FILE lixt-20240524_lab.xml EX-101.LAB 36769
5 XBRL PRESENTATION FILE lixt-20240524_pre.xml EX-101.PRE 25275
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5673
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 24999800
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)